Status:
COMPLETED
Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19
Lead Sponsor:
Alan Bryce
Conditions:
Severe Acute Respiratory Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To determine if the reduction in TMPRSS2 activity via direct inhibition with Camostat mesilate combined with standard of care (SOC) treatment will increase the proportion of patients alive and free fr...
Eligibility Criteria
Inclusion
- Laboratory confirmed SARS-CoV-2 infection
- Admitted to hospital for management of SARS-CoV-2
- Age ≥18
- Subject or legal representative able to give informed consent
- Ability to take all study drugs
- Respiratory status of 3 or greater on the WHO ordinal scale
- ALT or AST ≤5 x ULN
- Creatinine clearance ≥50 mL/min using the Cockroft-Gault formula
- Willingness to provide mandatory specimens for correlative research and banking
Exclusion
- Women who are pregnant or breastfeeding
- Known hypersensitivity to the study drug, the metabolites or formulation excipient
Key Trial Info
Start Date :
July 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 20 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04470544
Start Date
July 28 2020
End Date
January 20 2022
Last Update
November 12 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Arizona
Scottsdale, Arizona, United States, 85259
2
Tucson Medical Center
Tucson, Arizona, United States, 85712